Ranimustine
As of the edition of 20 October 2026, Ranimustine is a small molecule: marketed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed
- Kind
- Small molecule
- Brand name
- Cymerin
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Mitsubishi Tanabe Pharma
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Mitsubishi Tanabe Pharma | Originator |